Novo Nordisk mostly unaffected by COVID-19 in Q1

Novo Nordisk is with the exception of the postponement of new clinical trials mostly unaffected by COVID-19. Sales in Q1 were however positively affected by stock piling of insulin. Growth continues to be spearheaded by Ozempicยฎ, whereas Victozaยฎ and Levemirยฎ in the US continue to lead the decline. Rybelsusยฎ revenue totaled DKKb 229 in the …